Navigation Links
Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections

PHILADELPHIA, Oct. 30 /PRNewswire/ -- Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection. Preliminary results from a new study by the Henry Ford Health System evaluated records from patients who acquired SSTIs in hospital and healthcare settings and those who acquired similar infections in the community. Results from the study, which were presented today at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), also shed new light on baseline risk factors that are associated with inappropriate initial therapy (Abstract #053). This information may help guide clinicians in the appropriate treatment of SSTIs.


Complicated skin and skin structure infections (cSSTIs) account for almost 10 percent of all hospital admissions in the U.S.(1) According to the Centers for Disease Control and Prevention (CDC), approximately 25-30% of the U.S. population has some form of Staphylococcus aureus on their skin, and an increasing number of those individuals carry the more resistant form known as methicillin-resistant Staphylococcus aureus (MRSA).(2)(3)(4)

"Up to this point, the importance of initiating appropriate empiric* therapy has been well documented in other infections such as pneumonia, but not in skin infections," said study author Marcus Zervos, M.D. Division Head, Infectious Diseases, Director Infection Control at the Henry Ford Health System, in Detroit, MI. "These results show that a more comprehensive evaluation of hospital patient risk factors may help physicians determine the optimal initial antibiotic treatment, sparing patients unnecessary treatment and time in the hospital."

Risk Factors for Inappropriate Treatment

In the hospitalized patient population, three risk factors were identified as being associated with receiving inappropriate antibiotic treatment:

  • Healthcare-associated infection status (i.e., recent exposure within nursing homes, or medical clinics)
  • Presence of a "gram-negative" pathogen
  • Presence of a pathogen other than a Streptococcus species

Study Methods and Key Results

The study, conducted by the Henry Ford Health System with a grant from Ortho-McNeil Janssen Scientific Affairs, LLC, is an analysis of administrative and medical records of 368 patients hospitalized between late 2005 and 2008 with an admission diagnosis of a cSSTI. Patients were classified as having healthcare associated infections (HCAI) if they were: 1) recently hospitalized; 2) immunocompromised; 3) on hemodialysis; or 4) admitted from nursing home. All others were classified as having community-acquired infections (CAI). Initial empiric therapy (IET) was considered appropriate if antibiotics active against the infecting pathogen(s) were administered within 24 hours of admission.

Among patients with SSTIs whose infection was confirmed by culture ("culture-positive"), those who acquired an infection in a hospital or healthcare setting were more likely to be treated inappropriately than those who acquired an infection in a community setting (35.2% vs. 20.5%, p<0.01). Additionally, when other risk factors were adjusted, patients who received inappropriate initial therapy stayed in the hospital an average of nearly six days longer than patients who received appropriate initial therapy.

Moreover, the study showed that S. aureus was the most common pathogen in patients with both HCAI (55.6%) as well as CAI (58.2%), and the majority of these were methicillin-resistant S. aureus, commonly referred to as MRSA (73.4% in HCAI and 64.8% in CAI). MRSA represents a growing healthcare concern and has become an increasingly common cause of SSTIs, as evidenced by the prevalence of MRSA in this study.

Dr. Zervos is a principal investigator for the study and a paid consultant retained by Ortho-McNeil Janssen Scientific Affairs, LLC.

*Empiric treatment is defined as antibiotics prescribed prior to the identification of the causative pathogen(s) by culture results.

About Ortho-McNeil

Ortho-McNeil, Inc. is committed to providing innovative, high-quality prescription medicines, education and resources for patients, healthcare providers, and other members of the healthcare community in primary care, specialty and hospital settings. Based in Raritan, NJ, the company specializes in the areas of gastrointestinal and infectious diseases, pain management, women's health and urology, and has broad interest in other therapeutic categories. For more information, visit

(1) DiNubile MJ, Lipsky BA. Complicated Infections of skin and skin structures: when the infection is more than skin deep. JAC. 2004;53

(2) Halem M., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus skin infections. Semin. Cutan. Med. Surg. 25:68-71

(3) Kluytmans-Vandenbergh M.F., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12 Suppl 1:9-15

(4) Kollef M.H., and S.T. Micek. 2006. Methicillin resistant Staphylococcus aureus: a new community acquired pathogen? Curr. Opin. Infect. Dis. 19:161-168

Media Contact: Amy Firsching, 908-218-7583

SOURCE Ortho-McNeil, Inc.

SOURCE Ortho-McNeil, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
3. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)
6. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
7. AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
8. EntreMed Presents Initial Clinical Results for ENMD-2076
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
11. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Xavier University,s Center ... with Konica Minolta Medical Imaging (KMMI) on October 12. ... Thinking to help healthcare providers imagine and develop their ... roadmap that they can customize for their practice. ... is the initial procedure, or study, in medical imaging ...
(Date:10/9/2015)... BETHESDA, Maryland , October 9, 2015 ... Pharmaceuticals Inc. (OTCQB: CNBX) has announced its execution of ... Debt & Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, ... the company. --> --> ... internal restructuring of the Company, whereby the Research and ...
(Date:10/9/2015)... MELVILLE, N.Y. , Oct. 9, 2015 ... the world,s largest provider of health care products and ... today reminded its customers that the Henry Schein Disaster ... who experience operational, logistical or financial issues as a ... Carolina . The toll-free number for all ...
Breaking Medicine Technology:
... be showcased at National Health Service EXPOSAN JOSE, Calif., April ... ), a worldwide leader in medical devices for the minimally ... today announced that the UK NHS National Innovation Centre has ... a select innovative technology that is bringing benefits to National ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune diseases, today announced the filing of the first ... Nycomed for the anti-GM-CSF antibody MT203. Micromet received a ... Nycomed for the achievement of this milestone.Under a 2007 ...
Cached Medicine Technology:
(Date:10/9/2015)... , ... October 09, 2015 , ... A new health ... Exam Aid, is now available online ( ) – just in time for ... says officially begins in October. However, for many in the U.S., the real start ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... audiologists in The Tennessean's eighth annual Toast of Music City, a reader’s choice ... Nashville residents nominated and cast votes for their favorite businesses in over 200 ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... Stockton, CA (PRWEB) , ... October 09, 2015 ... ... year anniversary of their “Agents of Change” program, a community improvement initiative that ... The newest charity to benefit from the assistance of Confidence Plus Insurance is ...
(Date:10/9/2015)... ... 09, 2015 , ... Prescription Hope, the fastest growing pharmacy ... to save money on the high cost of their prescription medications through their ... and families can receive their medications delivered direct from over 180 U.S.-based pharmaceutical ...
Breaking Medicine News(10 mins):
... concern over skin cancer many people still disregard the use of ... was noticed that one in three Briton do not protect ... cases of skin cancer are diagnosed in the UK each year, ... will treble in the next 30 years. ,Research ...
... born in the United States -- more than double the ... for at least 21 serious disorders, according to the ... ,Massachusetts has failed to make progress on expanding the newborn ... District of Columbia require screening for the 29 core, treatable, ...
... shockingly thin during her performance at Hiro Ballroom on July ... about her emaciated appearance. ,The former Hole singer ... shake, then apologized to the crowd, saying that she "had ... Ensure shakes for my anorexia. You're going to have to ...
... make her sex scenes look realistic has landed her with ... recently admitted that she got into a painful problem while ... Steve Buscemi. ,The 25-year-old actress suffered head injuries ... ,"We were making out and I whacked my head really ...
... In a new study, UCLA researchers measured the effect of ... the physical symptoms of the disease and created ... may help clinicians guide treatment. The study appears in the ... revealed that to effectively treat hepatitis B patients, clinicians need ...
... overall cost-effectiveness of Medicare benefits have been much-debated, new ... receiving benefits at age 65 required more intensive ... insured prior to receiving Medicare. These findings, from researchers ... 12 issue of the New England Journal of Medicine. ...
Cached Medicine News:
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: